Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Brade

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 24, 2009
Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancerMax Dahele, Anthony Brade, Shannon Pearson, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|November 9, 2005
A positive prognosisAnthony Brade, Brian O'Sullivan, Bernard Cummings, et al.
Current Oncology (Toronto, Ont.)|April 30, 2021
A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung CancerAnthony Brade, Kevin Jao, Simon Yu, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2010
Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapyGwyn Bebb, Colum Smith, Stewart Rorke, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancerBarbara Melosky, Rosalyn Juergens, Deanna McLeod, et al.
Cancer Gene Therapy|December 19, 2003
Kinase-dead PKB gene therapy combined with hyperthermia for human breast cancerNancy Ma, Paul Szmitko, Anthony Brade, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2013
The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancerZishan Allibhai, Mojgan Taremi, Andrea Bezjak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 8, 2014
Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinomaShaelyn Culleton, Haiyan Jiang, Carol R Haddad, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2017
Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP studyLouise Murray, Joseph Longo, Jonathan Wan, et al.
Cancer Treatment and Research Communications|December 14, 2020
Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendationsDr Andrew G Robinson, Stephanie Snow, Anthony Brade, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|June 24, 2009
Stereotactic radiation therapy for inoperable, early-stage non-small-cell lung cancerMax Dahele, Anthony Brade, Shannon Pearson, et al.
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|November 9, 2005
A positive prognosisAnthony Brade, Brian O'Sullivan, Bernard Cummings, et al.
Current Oncology (Toronto, Ont.)|April 30, 2021
A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung CancerAnthony Brade, Kevin Jao, Simon Yu, et al.
Cancer Chemotherapy and Pharmacology|June 22, 2010
Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapyGwyn Bebb, Colum Smith, Stewart Rorke, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancerBarbara Melosky, Rosalyn Juergens, Deanna McLeod, et al.
Cancer Gene Therapy|December 19, 2003
Kinase-dead PKB gene therapy combined with hyperthermia for human breast cancerNancy Ma, Paul Szmitko, Anthony Brade, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2013
The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancerZishan Allibhai, Mojgan Taremi, Andrea Bezjak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 8, 2014
Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinomaShaelyn Culleton, Haiyan Jiang, Carol R Haddad, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 3, 2017
Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP studyLouise Murray, Joseph Longo, Jonathan Wan, et al.
Cancer Treatment and Research Communications|December 14, 2020
Applicability of the PACIFIC trial results in patients not eligible for the PACIFIC trial: Canadian rapid consensus statement and recommendationsDr Andrew G Robinson, Stephanie Snow, Anthony Brade, et al.
Pageof 6